Overview

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of interferon-beta-1a in subjects with active ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono
Collaborator:
Merck Serono International SA
Treatments:
Interferon beta-1a
Interferon-beta
Interferons